STIM Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -25.21% compared to Neuronetics, Inc.'s net margin of 12.65%. Neuronetics, Inc.'s return on equity of -153.53% beat Electromed, Inc.'s return on equity of 18.89%.

Neuronetics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 364.29%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Neuronetics, Inc. has higher upside potential than Electromed, Inc., analysts believe Neuronetics, Inc. is more attractive than Electromed, Inc..

Neuronetics, Inc. has a beta of 0.711, which suggesting that the stock is 28.865% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Neuronetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Neuronetics, Inc. quarterly revenues are $37.3M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Neuronetics, Inc.'s net income of -$9.4M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Neuronetics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics, Inc. is 0.62x versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies, Inc. has a net margin of -25.21% compared to Neuronetics, Inc.'s net margin of -1701.44%. Neuronetics, Inc.'s return on equity of -153.53% beat SINTX Technologies, Inc.'s return on equity of -208.36%.

Neuronetics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 364.29%. On the other hand SINTX Technologies, Inc. has an analysts' consensus of $12.25 which suggests that it could grow by 239.34%. Given that Neuronetics, Inc. has higher upside potential than SINTX Technologies, Inc., analysts believe Neuronetics, Inc. is more attractive than SINTX Technologies, Inc..

Neuronetics, Inc. has a beta of 0.711, which suggesting that the stock is 28.865% less volatile than S&P 500. In comparison SINTX Technologies, Inc. has a beta of 0.633, suggesting its less volatile than the S&P 500 by 36.717%.

Neuronetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics, Inc. pays -- of its earnings as a dividend. SINTX Technologies, Inc. pays out -- of its earnings as a dividend.

Neuronetics, Inc. quarterly revenues are $37.3M, which are larger than SINTX Technologies, Inc. quarterly revenues of $208K. Neuronetics, Inc.'s net income of -$9.4M is lower than SINTX Technologies, Inc.'s net income of -$3.5M. Notably, Neuronetics, Inc.'s price-to-earnings ratio is -- while SINTX Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics, Inc. is 0.62x versus 6.12x for SINTX Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -25.21% compared to Neuronetics, Inc.'s net margin of -862.39%. Neuronetics, Inc.'s return on equity of -153.53% beat VolitionRX Ltd.'s return on equity of --.

Neuronetics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 364.29%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 759.38%. Given that VolitionRX Ltd. has higher upside potential than Neuronetics, Inc., analysts believe VolitionRX Ltd. is more attractive than Neuronetics, Inc..

Neuronetics, Inc. has a beta of 0.711, which suggesting that the stock is 28.865% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Neuronetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Neuronetics, Inc. quarterly revenues are $37.3M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Neuronetics, Inc.'s net income of -$9.4M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Neuronetics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics, Inc. is 0.62x versus 17.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -25.21% compared to Neuronetics, Inc.'s net margin of 3.93%. Neuronetics, Inc.'s return on equity of -153.53% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Neuronetics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 364.29%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Neuronetics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Neuronetics, Inc. is more attractive than Xtant Medical Holdings, Inc..

Neuronetics, Inc. has a beta of 0.711, which suggesting that the stock is 28.865% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Neuronetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Neuronetics, Inc. quarterly revenues are $37.3M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Neuronetics, Inc.'s net income of -$9.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Neuronetics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics, Inc. is 0.62x versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.